Key Highlights

  • Haleon does not generate the headlines of a Diageo or a Vodafone, but the consumer-health group spun out of GSK in 2022 has become one of the FTSE 100's steadier performers.
  • The owner of Sensodyne, Panadol, Centrum, Voltaren, Advil and parodontax sits at the intersection of two powerful long-term trends, ageing populations and the shift towards self-care.
  • For the first half of 2026, Revenue rose 2.2% to £5,602 million, with organic revenue growth of 2.6% accelerating to 3.1% in the second quarter as Demand steadied.
  • That second-quarter growth was well balanced between price, up 1.7%, and Volume and mix, up 1.4%, a healthier composition than the price-led growth of recent years.

Haleon does not generate the headlines of a Diageo or a Vodafone, but the consumer-health group spun out of GSK in 2022 has become one of the FTSE 100's steadier performers. The owner of Sensodyne, Panadol, Centrum, Voltaren, Advil and parodontax sits at the intersection of two powerful long-term trends, ageing populations and the shift towards self-care, and its half-year results for 2026 underlined why some investors see consumer health as one of Britain's quietest structural growth themes. Valued at around £33 billion, Haleon offers defensive, brand-led exposure with a clear route to Margin expansion. The balance the market is watching is between that dependable defensiveness and a growth rate that has so far been solid rather than spectacular.

Half-year performance

For the first half of 2026, revenue rose 2.2% to £5,602 million, with organic revenue growth of 2.6% accelerating to 3.1% in the second quarter as demand steadied. That second-quarter growth was well balanced between price, up 1.7%, and volume and mix, up 1.4%, a healthier composition than the price-led growth of recent years. Adjusted operating profit climbed 8.2% at constant currency to £1,364 million, lifting the adjusted Operating Margin 120 basis points to 24.3%. Adjusted Diluted Earnings per Share rose 12% to 10.3p, and the Interim Dividend was increased 9% to 2.4p, signalling management's confidence in the earnings trajectory.

The Business model

Haleon's appeal lies in the durability of its franchises. Oral health, led by Sensodyne and parodontax, is its largest and fastest-growing category, complemented by pain relief, respiratory health, digestive health and vitamins. These are everyday products bought regardless of the economic cycle, supported by scientific credentials and heavy Marketing that create genuine pricing power. The group's strategy centres on 'power brands', innovation, geographic expansion into emerging markets, and productivity gains that fund both reinvestment and margin progression. A meaningful share of revenue comes from emerging markets, where rising incomes and greater health awareness offer a longer growth runway than Haleon's more mature Western strongholds. Chief executive Brian McNamara has consistently framed the business as a compounder capable of mid-single-digit organic growth over the medium term.

Balance sheet and Capital returns

Since demerger, deleveraging has been a priority, and net Debt has fallen to around 2.5 times adjusted EBITDA, giving Haleon growing flexibility to return cash. The company completed £457 million of a £500 million buyback allocation in the half, alongside its rising dividend, while free Cash Flow strengthened to £769 million. The exit of legacy GSK and Pfizer shareholders from the register, a long-running technical overhang, has largely cleared, removing a persistent source of selling pressure that had capped the shares for much of the group's early listed life.

Risks and softer patches

The story is not without blemishes. Growth has run at the lower end of the company's own 3% to 5% organic ambition, and a mild cold-and-flu season together with a more cautious American consumer weighed on parts of the range earlier in the year. Currency translation is a meaningful swing Factor for a group reporting in sterling but earning globally, private-label competition is a constant pressure in some categories, and any renewed input-cost Inflation could challenge margins. Litigation risk around certain products, while contained, has not entirely disappeared from the sector.

Outlook

Haleon reaffirmed full-year guidance of 3% to 5% organic revenue growth and high-single-digit adjusted operating profit growth at constant currency. Investors may watch whether the second-quarter acceleration is sustained, how volumes hold up against a subdued consumer, and the pace of further margin expansion and buybacks. The key question is whether Haleon can consistently deliver at the middle of its growth range; if it can, the market's quiet enthusiasm for consumer health as a defensive compounder could steadily build over time into something rather louder still.